ERBB2 and breast cancer: Notably, 16/26 patients (61.5%) whose tumors resembled the basal-like and HER2 enriched intrinsic breast cancer subtypes died from their disease within four years from diagnosis, compared to only 3/9 patients (33.3%) whose tumors displayed gene expression profiles corresponding to the luminal A and luminal B intrinsic breast cancer subtypes.